Alnylam Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 5576.75, 7293.9, 8735.88, 10104.76, 11677.84 ], "ebit_estimate": [ 1329.57, 1891.26, 2492.93, 3017.5, 3637.6 ], "ebitda_estimate": [ 1374.32, 1861.7, 2411.96, 3313.35, 4148.2 ], "net_income_estimate": [ 1025.5, 1526.52, 1942.93, 2344.04, 2937.06 ], "per_share_eps_estimate": [ 7.3, 10.97, 14.26, 16.16, 19.9 ], "eps_nri_estimate": [ 7.35, 10.88, 14.1, 16.21, 19.95 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 16, 29.88, 46.35, null, null ], "pretax_income_estimate": [ 1144.46, 1703.48, 2251.08, 2720.63, 3449.14 ], "operating_cash_flow_per_share_estimate": [ 9.68, 13.85, 11.98, null, null ], "roa_estimate": [ 18.83, 21.45, 0.21, 0.21, 0.2 ], "roe_estimate": [ 74.55, 44.63, 41.22, 32.1, 28.2 ], "gross_margin_estimate": [ 78.88, 78.16, 77.77, 77.75, 78 ], "operating_cash_flow_estimate": [ 1337.34, 1913.74, 1655.95, null, null ], "pettm_estimate": [ 40.95, 27.23, 20.95, 18.49, 15.01 ], "long_term_growth_rate_mean": 78.49, "long_term_revenue_growth_rate_mean": "32.77", "future_per_share_eps_estimate_growth": 79.37, "future_eps_nri_estimate_growth": 78.49, "future_revenue_estimate_growth": 32.77, "future_ebit_estimate_growth": 67.58, "future_ebitda_estimate_growth": 59.99, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 79.82, "future_pretax_income_estimate_growth": 86.28, "future_book_value_per_share_estimate_growth": 96.94, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -20.06, "future_gross_margin_estimate_growth": -1.54, "future_operating_cash_flow_per_share_estimate_growth": 45.24 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 1319.76, 1469.74, 1625.64, 1695.05, 1900.26, 2023, 2164.7, 2228.19 ], "ebit_estimate": [ 291.17, 343.25, 387.47, 395.04, 396.77, 406.33, 516.81, null ], "ebitda_estimate": [ 265.14, 345.07, 324.82, 285.8, null, null, null, null ], "net_income_estimate": [ 218.88, 269.42, 327.83, 325.64, 301.03, 325.06, 415.42, null ], "per_share_eps_estimate": [ 1.53, 1.88, 2.28, 2.5, 2.49, 2.87, 3.27, null ], "eps_nri_estimate": [ 1.58, 1.96, 2.37, 2.3, 2.49, 2.87, 3.27, 4.08 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, 5.96, null, null, null, null, null, null ], "pretax_income_estimate": [ 251.47, 299.79, 366.39, 406.57, 355.97, 380.73, 490.36, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 79.72, 77.54, 76.48, 75.9, 74.25, 73.65, 78.75, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 36.47, 32.63, 29.45, 26.85, null, null, null, null ], "long_term_growth_rate_mean": 78.49, "long_term_revenue_growth_rate_mean": "32.77", "future_per_share_eps_estimate_growth": 79.37, "future_eps_nri_estimate_growth": 78.49, "future_revenue_estimate_growth": 32.77, "future_ebit_estimate_growth": 67.58, "future_ebitda_estimate_growth": 59.99, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 79.82, "future_pretax_income_estimate_growth": 86.28, "future_book_value_per_share_estimate_growth": 96.94, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -20.06, "future_gross_margin_estimate_growth": -1.54, "future_operating_cash_flow_per_share_estimate_growth": 45.24 }